SCHEMBL2195637

SCHEMBL2195637

COc1ccc(Cn2ccn(C)c2=[Pt])cc1OC.Fc1ccc(CN(I)I)cc1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 2/20 0.38
TP53 P04637 1/20 0.38
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
SIGMAR1 Q99720 1/20 0.36
POLB P06746 2/20 0.36
CSF1R P07333 1/20 0.36
DBH P09172 1/20 0.36
KMT2A Q03164 1/20 0.36
QPCT Q16769 2/20 0.35
HPGD P15428 1/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2194560 0.90 L3MBTL1 (0.41) L3MBTL1SIGMAR1LMNA
SCHEMBL2194395 0.89 MAPK10 (0.38) MAPTTP53KDM4ESMN1; SMN2SIGMAR1
SCHEMBL2195285 0.89 LMNA (0.39) MAPTALDH1A1SMN1; SMN2SIGMAR1CSF1R
SCHEMBL2195518 0.86 DBH (0.38) MAPTALDH1A1KDM4ESMN1; SMN2SIGMAR1
SCHEMBL2193843 0.85 MET (0.43) MAPTTP53ALDH1A1KDM4ESMN1; SMN2
SCHEMBL2195305 0.85 LPO (0.52) MAPTTP53ALDH1A1KDM4EKMT2A
SCHEMBL2192101 0.79 SIGMAR1 (0.45) MAPTALDH1A1KDM4ESMN1; SMN2SIGMAR1
SCHEMBL2194916 0.79 MAPT (0.47) ATML3MBTL1MAPTTP53ALDH1A1
SCHEMBL2197400 0.79 ALDH1A1 (0.33) MAPTALDH1A1
SCHEMBL2192874 0.78 SIGMAR1 (0.44) MAPTALDH1A1KDM4ESMN1; SMN2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 PTPN1 3746/4885ATM 2266/4885L3MBTL1 2187/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 PTPN1 3746/4885ATM 2266/4885L3MBTL1 2187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.